Immunomodulating medication based on Fc fragments of human IgG
US4719107A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 7, 1984 |
| Grant date | Jan 12, 1988 |
| Priority date | — |
| Expiry date | Dec 7, 2004 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/868
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This medication consists of Fc fragments of human IgG, or of analogues of said fragments, and [is characterized by the fact] that it is free of intact IgG and/or Fab fragments or contains no more than 2% by weight of the latter with respect to total weight (Fc+Fab+IgG), it being understood that said analogues of Fc fragments of human IgG are all fragments or subfragments of Fc and all synthetic or semisynthetic peptides containing peptide sequences present in the Fc fragment, as well as all derivatives of these fragments, subfragments, or peptides, provided that these fragments, subfragments, peptides, or derivatives fulfill the following conditions: PA1 they have properties that activate the differentiation of suppressive cells; PA1 they have properties that inhibit antibody-dependent cytotoxicity; PA1 they do not have properties that activate NK cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.